Biopharmaceutical companies continue to reveal restructuring plans and job cuts even as valuations overall are improving, with many second quarter earnings calls revealing a wave of actions aimed at conserving cash. Despite the recent upswing in biopharma stocks in general, many companies still find it difficult to raise funds, especially after clinical trial setbacks, and are looking for ways to extend their cash runways.
Homology Medicines, Inc., which had a more than 26% rise in its stock price during the past month, still...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?